Adding complexity to early trials is the issue of interpreting a rising PSA, the most commonly measured marker of response in prostate cancer, in the context of potential activation of AR transcription with resultant PSA rises following PI3K pathway inhibition. The gene discussed is PIK3CB; the disease is Familial prostate cancer.